Index

Acceptable daily intake (ADI), 53 Acquired immunodeficiency syndrome (AIDS), 87, 100	Chemical mixtures, 59-60 chemical-specific data development, 5,92-93
Advisory Committees, 109-110	Clean Air Act, 102, 106
Agency for Toxic Substances and Disease Registry (ATSDR),	Collaboration, 19, 173
46,78,98	disciplinary bridges, 181-182
Agent Orange, 131, 134-135	government interagency, 75
Agricultural Health Study, 75	need for, 82
Ambient monitoring, 50	with the private sector, 182-183
Animal bioassays, 55,68, 120-121, 135	with universities, 183, 184
Association of California Water Agencies, 161-162	Compliance costs, see Costs
Assumptions, conservative; see Science policy assumptions	Comprehensive Environmental Response, Compensation,
Basic research, 4-5,92, 179	and Liability Act (CERCLA), 102, 107
Benzene, 46, 102	Consumer Product Safety Commission (CPSC)
Biological monitoring, 50, 136	health risk assessment at, 46
Biologically based dose-response models, 177	health risk assessment research at, 80
Biomarkers, 175, 176	research priorities for, 102
Bridging studies, 82	and scaling factors, 123-124
Bromley, D. Allan, 101	costs
Brookhaven National Laboratory, 160	of compliance with regulations, 2, 61-62 of environmental cleanup, 61
Cancer	of environmentally related illnesses, 2, 62-63
genetic predisposition to, 180	Crosscuts, 101
and power-line electromagnetic fields, 130-131	Cross-species extrapolation, 124-125
risk from indoor radon, 159-161	Cross-species extrapolation factors, see Scaling factors
role of oncogenes and tumor suppressor genes in, 178, 180	
Carcinogens	Data development and management, 179-181
animal bioassays in assessing, 55,58	Decision, Risk, and Management Science (DRMS) program
guidelines for risk assessments of, 120-125	140
and International Agency for Research on Cancer guidelines, 128, 129	Decisionmaking, see Regulatory decisionmaking Department of Agriculture, 80-81,98
linearized, multistage model for, 52,59	Department of Defense
risk assessment of, 46	federal support for health risk assessment research, 98
thresholds for, 46,52, 127	health risk assessment research at, 79-80
Center for Devices and Radiological Health, 77	priority-setting, 80, 103
Center for Environmental and Molecular Biology of the	influence of management style on priorities, 109
Lung, 69	Department of Energy
Center for Food Safety and Applied Nutrition, 8,74,109,	federal support for health risk assessment research, 98
104, 105	health effects research at, 78-79
Centers for Disease Control and Prevention (CDC), 46,77-78	health risk assessment research budget at, 78,79
Chaffee-Lautenberg Amendment, 157-158	priority-setting, 79, 103, 109

226 I Researching Health Risks

priority-setting, 79, 103, 109 role of national laboratories in health risk assessment research, 79 and study of electromagnetic fields, 131 targeted vs. basic research, 112-113 Department of Health and Human Services, 70-78; see also specific constituent agencies Dioxin and carcinogenicity, 131 effects in chemical mixtures, 59-60 National Institute of Environmental Health Sciences research on, 73 and the "Ranch Hands," 134-135 Dose-response assessment, 51-52, 177-179	resources for health risk assessment research, 103 Federal Coordinating Council on science, Engineering, and Technology (FCCSET), 7,100-102 Federal Insecticide, Fungicide, and Rodenticide Act, 92, 102, 106 Food and Drug Administration early use of extrapolation models, 46 federal support for health risk assessment research, 98 health risk asses-t research at, 74,776-77 lack of data analysis at, 82 priority setting at, 6 and scaling factors, 123-124 Friends of the Earth, 159, 161, 162 Funding mechanisms, 110-111
Electric Power Research Institute, 131 Electromagnetic fields (EMFs), power-line, 130-131 Environmental Health Sciences Center, 184 Environmental Protection Agency (EPA)	Guidelines for developmental toxicity, 126 for exposure assessment, 126 for carcinogens, 120-123
and Agricultural Health Study, 75 as expert agency, 99 developmental toxicity guidelines, 126 and dioxin, 132-133 factors determining response to new research, 127-128 federal support for health risk assessment research at, 95, 98 exposure assessment guidelines, 126 guidelines for risk assessment of carcinogens, 120-123 health risk assessment at, 46 health risk assessment research at, 68-69 lack of data analysis at, 82 and no-threshold assumption for carcinogens, 127 priority-setting at, 6,70, 102, 109 and regulation of indoor radon, 145-167 resources for health risk assessment research, 9, 104, 105 risk communication research, 140 Science Advisory Board, 109-110, 157	Habicht, F. Henry, 54,60 Hazard identification, 50-51,60,71-72 Health Effects Research Laboratory (HERL), 68, 102 Health risk assessment controversial issues in, 54-60 coordination of, 46 definition, 20,47 as formal scientific field, 139 as four-step process, 1, 50-54 growth m federal government, 46 numerical expression of, 1,47 relationship of research and management to, 51 and risk managers, 48 strengths of, 54 uses of, 47 uncertainty in, 60 Health risk assessment research
and scaling factors, 123-124 science policy positions for carcinogen assessment guidelines, 122 validation studies at, 82 Environmental Research and Development Demonstration	agency priorities for, 102-108 bridging studies in, 82 classification of, 3-4, 88-93; see <i>also specific categories</i> and changes in presumptions for extrapolations, 125 characteristics of high-quality studies, 19, 172-174
Act (ERDDA), 102, 109 Epidemiologic studies on indoor radon, 149-153 limitations for assessing risk, 134-135	definition of, 67 federal government activities in, 67-83; see <i>also specific</i> agencies federal resources for, 5-6,93-98
as primary data source for health risk assessment, 48-49 Exposure assessment 50,52-53,95,126,177 Extrapolations, 1,20,52,59	future prospects, 174-181 influence of legislative branch on priorities for, 101 issues and options, 20-44 limits of impact on guidelines, 126-128
Federal agencies, see <i>also specificagencies</i> collaborations with universities, 69 health risk assessment research at, 67-83 priorities for health risk assessment research, 102-108	multidisciplinary efforts in, 81-82 normal vs. mandated, 88-89 rationale for, 60-63 by regulatory agencies, 102-103

and regulatory decisionmaking, 119-140	role of advisory committees, 110
by research agencies, 103	targeted research at, 112
resources for, 103, 104, 105	National Institute of Environmental Health Sciences
setting priorities for, 7-10, 87-1 15; see also specific	(NIEHS)
agencies	and Agricultural Health Study, 75
structuring future efforts, 171-184	carcinogenicity-related research at, 72, 82
trends and gaps in federal activities, 10-12, 81-82	federal support for health risk assessment research, 95,98
Homeobox genes, 179	health risk assessment research at, 72-73
Human exposure testing methods, 177	methodological research at, 73
Human Genome Project, 19, 78, 112, 179, 182	priority-setting, 6,72-73, 109
I 40	quantitative health risk assessment research at, 73
Immunotoxicity, 49	resourses for health risk assessment research, 9, 104, 105
Indoor air pollution, 164	role of advisory committees, 110
Indoor Radon Abatement Act (IRAA), 17, 146, 163	National Institute for Occupational Safety and Health
Interagency Regulatory Group, 46	(NIOSH)
International Agency for Research on Cancer (IARC), 128,	collaborative evaluation studies at, 82
128	federal support for health risk assessment research, 8,98
International risk assessment, 187-207	
Landanianian (2.62	health risk assessment at, 46,78 health risk assessment research at, 77-78
Lead poisoning, 62-63 Linearized, multistage model (LMS), 52,59	· · · · · · · · · · · · · · · · · · ·
	National Research Council, 2,54,56-58, 137
Lowest-observed-adverse-effect level (LOAEL), 53	National Research Council Committee on the Institutional
Lowest-observed+ffect level (LOEL), 53	Means for Assessment of Risks to Public Health, 137
Management, program, 10, 108-109	National Science Foundation (NSF), 140
Margin of safety, 53	National Science and Technology Council, 10, 101
Maximum tolerated dose (MTD), 55,58	National Toxicology program (NIT)
Mechanisms of toxicity, 68	as arbiter of toxicity testing priorities, 99
Mechanistically based dose-response modeling, 177	collaborative evaluation studies at, 82
Meta-analysis, 181	controversy over testing priorities, 89
Methodological research, 4,91-92	lack of data analysis at, 82
federal support for, 6,95,96	health risk assessment research at, 71-72
	toxicity testing at, 71-73
new methods for toxicity studies, 175	National Resources Defense Council, 159, 161, 162
lack of incentives for, 103, 108	Neurotoxicity, 49
Methylene-chloride, 124-125	No-observed-adverse-effect level (NOAEL), 51-52,53
Mine Safety and Health Administration (MM-IA), 77	No-observed-effect level (NOEL), 46,51-53,53
Mission-oriented research, 98	North Atlantic Treaty Organization (NATO), 132-133
Molecular epidemiology, 175, 176	Nuclear Regulatory Commission, 46,81
Multidisciplinary research, 81-82, 139; see also	reactar regulatory commission, 10,01
Collaboration	Occupational Safety and Health Act, 102, 103, 107
National Cancer Institute	Occupational Safety and Health Administration (OSHA)
and Agricultural Health Study, 75	and benzene regulation, 46, 102
	health risk assessment at, 46
epidemiologic research at, 74	priorities for research, 102
federal support for health risk assessment research, 93,95,	as regulatory office, 77
98	Office of Management and Budget (OMB)
health risk assessment research at, 73-75	and conservative science policy assumptions, 55
priority-setting, 6,74, 109	as influence on national priorities for health risk
resources for health risk assessment research, 8, 104, 105	assessment research, 101
role of advisory committees, 110	use of science to attack risk assessment, 127-128
National Center for Environmental Health (NCEH), 77	Oncogenes, 178
National Center for Toxicological Research (NCTR)	One-hit model, 59
federal support for health risk assessment research, 95,98	Office of Science and Technology Policy (OSTP), 46, 101
health risk assessment research at, 74,76-77	
resources for health risk assessment research, 9, 104, 105	Peer review, 110-111

228 Researching Health Risks

Personal monitoring, 50, 136 Physiologically based pharmacokinetic (PBPK) model, 124-	health risk assessment research at, 68-70 program emphases, 113
125, 177	targeted research at, 112
Priority-setting, 7-10,87-115	Research linkages, see Collaboration
administrative tools for, 109-113	Resource Conservation and Recovery Act (RCRA), 102,107
at the agency level, 10, 102-108; see also specific agencies	Risk
funding mechanisms to support, 110-111	definition, 1
influence of agency "culture" on, 108	from familiar hazards, 47
influence of leadership on, 109	from indoor air pollution, 164-165
at the national level, 7-8,98-102	public perception of, 47-48
at the program level, 10, 108-109	quantification of, 1,47
Proto-oncogenes, 178	regulation of, 48
Radon, indoor, 14-19, 145-167	Risk assessment, see Health risk assessment
action levels for, 16, 17, 155-156	Risk-based planning, 70
benefits of new studies of, 166-167	Risk characterization
cancer risk estimates, 15, 17, 159-161	for carcinogens, 53-54
and Chaffee-Lautenberg Amendment, 157-158	_
cost-effectiveness analysis for reducing concentrations,	for noncarcinogens, 53
16, 156, 157	single numerical risk estimate in, 54
costs of regulation, 161-162	uncertainty factors in, 53
ecological fallacy, 150, 151	use of distributional approach in, 139-140
EPA Science Advisory Board comments on, 17, 18, 157,	Risk communication, 140
161, 162-163	Risk management, 51
epidemiologic studies of, 149-153	Safe Drinking Water Act, 15, 16, 102, 107, 145, 156-157,
exposure levels for airborne, 16, 155-156	158, 163
exposures from uranium mines, 146-147	Safety factors, see Uncertainty factors
importance of appropriate testing techniques, 154-155	Scaling factors, 52,54, 123-124
inconsistency in EPA's approach to, 17-19, 163-164	Science policy assumptions, 1, 12-14,20,54-55
and lung cancer, 16, 145, 148, 150-153, 155	Structure-activity relationships, 50,70, 175
magnitude of waterborne problem, 146	Superfund Amendments and Reauthorization Act, 107
policy on airborne radon, 154-156	•
regulatory decisionmaking on waterborne radon, 156-163	Targeted research, 112-113
role in other cancers, 153-154	2,3,7,8 -tetrachlorodibenzo-p-dioxin (TCDD), see Dioxin
and smoking, 148, 151-152	Toxic Substances Control Act, 92, 102, 106
Reference dose (Rfd), 53	Toxicity equivalence factor (TEF) procedure, 132-133
Regulatory decisionmaking	Toxicological studies, 49-50
and benzene, 46	basic vs. applied, 88
compliance costs of, 61-62	chemical specific, 92-93
conservative science policy assumptions as basis for, 55	endpoints of, 49
and costs of environmentally related illnesses, 62-63	as primary data source for health risk assessment, 49-50
and dioxin, 131-133	and mechanistic research, 99-100
and indoor radon, 145-167	Tri-Services Center for Toxicology and R&k Assessment, 80
legislation regulating toxic substances, 106-107	Tumor suppressor genes, 178
limits of science in, 14, 133-137	Uncertainty characterization, 60
links to research, 12-14, 137-140	Uncertainty factors, 46,52,53
social and political factors in, 136-137	Uranium Mill Tailings Radiation Control Act, 147-148
studies on feedback to researchers from, 133 Reilly, William K., 136	<u>-</u>
Reproductive and developmental toxicity, 49	Validation studies, 68
Research to Improve Health Risk Assessment (RIHRA)	Watras, Stanley, 148
program	mana, Stantoj, 110